Article Text

PDF
Which MAO-B inhibitor for Parkinson’s disease?

Statistics from Altmetric.com

Review of: Binde CD et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br J Clin Pharmacol 2018;84:1917–27.

Key learning points

  • In the UK, three monoamine oxidase type B (MAO-B) inhibitors are licensed for the treatment of Parkinson’s disease.

  • There are no published trials that have directly compared all MAO-B inhibitors with each other.

  • The results of a meta-analysis suggest that selegiline may be superior when used in combination with levodopa.

The authors of a meta-analysis suggest there is little to choose between monoamine oxidase type B (MAO-B) inhibitors as monotherapy for Parkinson’s disease, but selegiline may be superior when used in combination with levodopa.1

Overview

A meta-analysis (27 randomised trials; 7 578 participants) compared the relative efficacy of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.